117 related articles for article (PubMed ID: 33393037)
1. Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype.
Pawloski KR; Wen HY; Tadros AB; Abbate K; Morrow M; El-Tamer M
Ann Surg Oncol; 2021 Aug; 28(8):4256-4262. PubMed ID: 33393037
[TBL] [Abstract][Full Text] [Related]
2. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
[TBL] [Abstract][Full Text] [Related]
3. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
4. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
5. Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?
Grabenstetter A; Brogi E; Chou JF; Morrow M; Dickler M; Norton L; Wen HY
Ann Surg Oncol; 2019 Feb; 26(2):329-335. PubMed ID: 30298311
[TBL] [Abstract][Full Text] [Related]
6. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
9. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
10. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
[TBL] [Abstract][Full Text] [Related]
11. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
12. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
13. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
14. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Turashvili G; Brogi E; Morrow M; Hudis C; Dickler M; Norton L; Wen HY
Breast Cancer Res Treat; 2017 Aug; 165(1):65-76. PubMed ID: 28577081
[TBL] [Abstract][Full Text] [Related]
15. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
16. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
17. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
[TBL] [Abstract][Full Text] [Related]
18. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
19. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]